Candel Therapeutics
IPOPioneering Precision Viral Immunotherapy for Patients Fighting Solid Tumors
Public · Needham, United States · Founded 2020 · $180.0M raised
- Headquarters
- Needham, Massachusetts
- Employees
- 11–50
- Founded
- 2020
- Business Model
- B2B
- Website
- candeltx.com
- Total Funding
- $180.0M
- Last Round
- $100.0M Venture RoundFeb 2026
- Rounds
- 3
- Type
- Public
About
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf multimodal viral immunotherapies for solid tumors. Its platforms are designed to cause in-situ immunization by inducing tumor cell lysis and stimulating both innate and adaptive immune responses. Candel's investigational therapies target durable clinical benefit across multiple cancer indications, including prostate cancer, lung cancer, and glioblastoma.
Summary
Candel Therapeutics is a Biotech company based in Needham, United States, founded in 2020. It has raised $180.0M in total across 3 rounds, most recently a $100.0M Venture Round round in Feb 2026.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Feb 2026
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...